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To the Editor:
The economics of robotic prostatectomy are very impor-
tant, considering the fact that prostate cancer is the most
common cancer in men and radical prostatectomy is one
of the main treatments for localized disease. The rapid
adoption of robotic prostatectomy has resulted in the
widespread availability of robotic systems and significant
utilization by surgeons with little prior laparoscopic expe-
rience.1 The study by Steinberg et al2 evaluates the poten-
tial cost-benefit of adopting the robotic approach to an
established laparoscopic program. This study found that it
is possible that an increase in surgical volume will result in
sufficient profits to offset the added cost of the robot
(purchase cost of $1.5 million plus maintenance cost) and
equipment. A major requirement is that robotic prostatec-
tomy will be profitable for a hospital and that a sufficient
rise in surgical volume is achievable. The authors con-
clude that a high-volume laparoscopic radical prostatec-
tomy (LRP) program can convert to robot-assisted prosta-
tectomy (RAP) and maintain profitability but may not
reach the level of LRP.
I think that the issue of achieving profitability is very
important for hospitals that take on the entire burden of
purchasing and maintaining the robot. If hospitals lose
money on their robotics program, then this may sway
further hospitals in competitive markets from purchas-
ing a robot. One of the key assumptions in this article is
that the cost of disposables for the robot is only $200/
case. This seems to be unreasonable as each robotic
case requires a minimum of 4 instruments (scissors,
grasper, and 2 needle drivers), and robots with 4 arms
will use 5 or 6 instruments. Since each instrument costs
over $2000 and has a limit of 10 uses, there is a mini-
mum added cost of over $1000 per case over the cost of
an LRP. Furthermore, the authors assume a profit of
$5,409 per case. This profit may be achievable with
certain insurance companies, but Medicare reimburses
around $7,000 per case such that a high profit margin is
not achievable for many patients who are over 65.
Based on the above consideration, it is unlikely that the
predictions regarding the profitability of RAP will be
achievable under current market conditions. A decrease
in the cost of the robot and/or equipment will be
required to improve the cost-effectiveness of RAP.
Finally, as more hospitals obtain a robot, the added draw
of having a robot diminishes such that acquiring a robot
may not significantly increase the patient volume for the
fourth or fifth hospital in a region compared with the first
or second robot in the region.
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Authors’ Response
Dear Editor:
Dr. Lotan’s comments regarding our cost analysis of im-
plementing a robotic prostatectomy program are well
taken. With regard to the added costs of instruments, the
figure of $200 per case was $200 above the cost per case
of laparoscopy instruments at our center. The absolute
cost of the instruments per case is, as Dr. Lotan sites,
roughly $1000. Our figure underestimates the difference
in cost between the laparoscopic and robotic approaches,
as it was derived from institution-specific data and is
subject to local variation; however, the $400,000 annual
cost of the robot and service contract remain the bulk of
additional cost at all but the highest volume centers.
Secondly, with regards to Medicare reimbursement for this
procedure, the average age in the Henry Ford Hospital
experience is 60.2 years for patients undergoing robotic-
assisted radical prostatectomy.1 Certainly, a center oper-
ating on a large number of Medicare beneficiaries stands
to decrease its income relative to a center with fewer
beneficiaries, but in this large series the average age is
below the minimum for Medicare.
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LETTER TO THE EDITORThe clear relationship between volume and income with
this procedure is a critical factor for any hospital seeking
the development of a robotics program and the purchase
of a robot. In our estimation, the caseload a center can
expect is the critical factor in the decision to purchase a
surgical robot, as it only pays for itself if it is utilized, in the
same manner as an airplane. Other factors, such as attract-
ing other patients to a center, recruitment of physicians
and merely “keeping up,” are important, but these effects
are less easily discerned than the relationship between a
large surgical caseload offsetting the expense of the robot.
Our paper was meant to temper the enthusiasm for this
technology at low-volume centers, where the addition of
robotics to the array of services of such centers may lead
to financial harm, and prevent healthcare dollars from
being more appropriately allocated.
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